Week of Mar. 12, 2012: AstraZeneca Files Suit Against FDA; Pfizer, Biocon Terminate Biosimilar Alliance; and More - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Week of Mar. 12, 2012: AstraZeneca Files Suit Against FDA; Pfizer, Biocon Terminate Biosimilar Alliance; and More

ePT--the Electronic Newsletter of Pharmaceutical Technology

AstraZeneca filed a lawsuit against FDA in the United States District Court for the District of Columbia to overturn the FDA’s Mar. 7, 2012 denial of Citizen Petitions filed by AstraZeneca with regard to the Seroquel (quetiapine fumarate) tablets and Seroquel XR extended-release tablets, a treatment for bipolar disorder. AstraZeneca seeks an injunction which would bar FDA from granting final marketing approval of generic quetiapine until Dec. 2, 2012, when regulatory exclusivity expires on important clinical trial data, or at least until a federal court has a meaningful opportunity to review imminent FDA action regarding the pending generic marketing applications. Read More

The biotechnology company Biocon and Pfizer have ended their alliance to commercialize Biocon’s biosimilar versions of Insulin and Insulin analog products. The companies have agreed that, due to the individual priorities for their respective biosimilars businesses, it is in their best interest to move forward independently. Read More

DSM, the custom manufacturing business of Royal DSM, and the biopharmaceutical company Agennix have signed a new contract under which DSM will manufacture the oral dendritic cell mediated immunotherapy talactoferrin for Agennix at commercial levels in anticipation of positive Phase III clinical-data and product approval. DSM is currently manufacturing talactoferrin for use in ongoing clinical trials, including the Fortis-M trial in nonsmall cell lung cancer, and will continue to supply talactoferrin for clinical trials as well as to support a potential commercial launch. Read More

The Generic Pharmaceutical Association (GPhA) has pledged its support to the Pharmaceutical Traceability Enhancement Code (RxTEC), a new system for ensuring the security of the US pharmaceutical supply chain. The RxTEC model, which was developed by the Pharmaceutical Distribution Security Alliance, a multistakeholder initiative designed to increase patient access to safe medicines while improving the security of the American drug-distribution system. Read More

Industry Briefs:

A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here